Workflow
Bellevue Life Sciences Acquisition (BLAC) - 2023 Q4 - Annual Report

Business Combination and Compliance - The company must complete its initial business combination by May 14, 2024, or it will cease operations and liquidate, raising substantial doubt about its ability to continue as a going concern [70]. - If the initial business combination is not completed, public stockholders may only receive 10.175pershareuponredemption,whichcouldbelessincertaincircumstances[73].ThecompanyhasextendedthedeadlineforcompletingabusinesscombinationfromNovember14,2023,toFebruary14,2024,withpotentialfurtherextensionstoMay14,2024,contingentuponadditionaldepositsintotheTrustAccount[104].Thecompanymustcompletebusinesscombinationswithanaggregatefairmarketvalueofatleast8010.175 per share upon redemption, which could be less in certain circumstances [73]. - The company has extended the deadline for completing a business combination from November 14, 2023, to February 14, 2024, with potential further extensions to May 14, 2024, contingent upon additional deposits into the Trust Account [104]. - The company must complete business combinations with an aggregate fair market value of at least 80% of the assets held in the Trust Account [116]. - The company will only complete an initial business combination in which it owns or acquires 50% or more of the outstanding voting securities of the target [163]. - The company plans to complete its initial business combination with a target business that may be financially unstable or in early stages of development, which carries inherent risks [128]. - The company will seek stockholder approval for its initial business combination, requiring a majority vote from outstanding shares present at the meeting [197]. - If stockholders do not conduct redemptions in connection with the initial business combination, a restriction will limit redemption rights to 15% of shares sold in the IPO [198]. - The company will conduct redemptions in accordance with SEC regulations if a stockholder vote is not required for the initial business combination [147]. - The company will only redeem public shares if net tangible assets remain at least 5,000,001 after the redemption [205]. - The company’s Sponsor, officers, and directors have waived rights to liquidating distributions from the Trust Account for founder shares if the initial business combination is not completed within the specified timeframe [203]. - Claims against the Trust Account may have higher priority than claims from public stockholders, potentially reducing the actual redemption amount received [206]. - The company intends to redeem public shares as soon as reasonably possible following the 15th month after the IPO, which may expose stockholders to potential liabilities [211]. - The company cannot assure that the actual value of the per share redemption price will not be less than 10.175perpublicshareduetopotentialclaimsbycreditors[212].Thecompanyhasnotreservedforindemnificationobligationsrelatedtoclaimsbythirdparties,whichmayaffecttheTrustAccount[208].Ifbankruptcyoccurs,theproceedsheldintheTrustAccountcouldbesubjecttoclaimsofthirdparties,potentiallyimpactingstockholderreturns[212].Stockholderscouldbeliableforclaimstotheextentofdistributionsreceived,whichmayextendbeyondthethirdanniversaryofthedissolutiondate[211].FinancialManagementandReportingAsofApril16,2024,thecompanyreplacedapproximately10.175 per public share due to potential claims by creditors [212]. - The company has not reserved for indemnification obligations related to claims by third parties, which may affect the Trust Account [208]. - If bankruptcy occurs, the proceeds held in the Trust Account could be subject to claims of third parties, potentially impacting stockholder returns [212]. - Stockholders could be liable for claims to the extent of distributions received, which may extend beyond the third anniversary of the dissolution date [211]. Financial Management and Reporting - As of April 16, 2024, the company replaced approximately 562,000 in funds that were improperly used for operating expenses, ensuring compliance with the Trust Agreement [76]. - A total of 3,432,046 shares were tendered for redemption at a price of approximately 10.49pershare,resultinginanaggregateredemptionamountof10.49 per share, resulting in an aggregate redemption amount of 35,995,727.58 [77]. - The company deposited 60,000intotheTrustAccountonFebruary9,March12,andApril9,2024,aspartofitsextensionstrategyforthebusinesscombinationdeadline[77].Thecompanyhasdeposited60,000 into the Trust Account on February 9, March 12, and April 9, 2024, as part of its extension strategy for the business combination deadline [77]. - The company has deposited 180,000 into the Trust Account as part of the extension agreement [104]. - As of December 31, 2023, the company had 34,535,106availableintheTrustAccountforaninitialbusinesscombinationafterpaying34,535,106 available in the Trust Account for an initial business combination after paying 2,070,000 in deferred underwriting fees [127]. - The aggregate market value of the voting stock held by non-affiliates of the Registrant on June 30, 2023, was approximately 70.794millionbasedonaclosingpriceof70.794 million based on a closing price of 10.26 per share [218]. - The company has identified material weaknesses in its internal control over financial reporting as of December 31, 2023 [352]. - Management believes that the financial statements included in the Annual Report present fairly the financial position and results of operations for the period presented [352]. Strategic Focus and Management - The company anticipates structuring its initial business combination to acquire 100% of the equity interests or assets of the target business or businesses [90]. - The company plans to focus on acquiring a healthcare holding company with interests in biopharmaceuticals, medical devices, and healthcare technology, emphasizing a diversified portfolio approach [113]. - The management strategy includes strong financial management and regulatory expertise to navigate the healthcare industry's complexities [115]. - The management team has developed a broad network of contacts in the healthcare and biotechnology industry, which will aid in identifying potential business combination targets [122]. - The company intends to focus its search for an initial business combination in a single industry, which may expose it to risks associated with a lack of diversification [136]. - The company may seek to recruit additional managers to enhance the management of the target business post-combination [138]. - The company has committed to a monthly payment of 7,500toBellevueCapitalManagementLLCforadvisoryservicesrelatedtotheinitialbusinesscombination[102].ComplianceandRegulatoryMattersThecompanysubmittedaplantoNasdaqtoregaincompliancewiththeMinimumPublicHoldersRequirementafterbeingnotifieditnolongermettherequirement[85].ThecompanyhasuntilJune21,2024,toregaincompliancewithNasdaqListingRule5605(c)(2)(A)followingadirectorsresignation[83].Thecompanyisclassifiedasan"emerginggrowthcompany,"allowingittotakeadvantageofcertainreportingexemptions[97].Thecompanyisclassifiedasa"smallerreportingcompany"andwillmaintainthisstatusuntilitmeetscertainrevenueandmarketvaluethresholds,specifically7,500 to Bellevue Capital Management LLC for advisory services related to the initial business combination [102]. Compliance and Regulatory Matters - The company submitted a plan to Nasdaq to regain compliance with the Minimum Public Holders Requirement after being notified it no longer met the requirement [85]. - The company has until June 21, 2024, to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) following a director's resignation [83]. - The company is classified as an "emerging growth company," allowing it to take advantage of certain reporting exemptions [97]. - The company is classified as a "smaller reporting company" and will maintain this status until it meets certain revenue and market value thresholds, specifically 250 million in market value or 100millioninannualrevenues[98].ThecompanyisevaluatingitsBoardandAuditCommitteecompositiontocomplywithNasdaqsrequirements[110].FundingandFinancialResourcesThecompanyissuedanunsecuredpromissorynotefor100 million in annual revenues [98]. - The company is evaluating its Board and Audit Committee composition to comply with Nasdaq's requirements [110]. Funding and Financial Resources - The company issued an unsecured promissory note for 1,200,000 to fund working capital, payable by December 31, 2024, or upon consummation of a Business Combination [112]. - The company may seek to raise additional funds through a private offering of debt or equity securities to complete its initial business combination [159]. - The company is not currently a party to any binding agreement for raising additional funds through the sale of securities [159]. - The company will fund all costs and expenses associated with its dissolution from amounts held outside the Trust Account, with a potential request for up to $100,000 of accrued interest if necessary [187]. - The company aims to have all vendors and service providers execute agreements waiving claims to the Trust Account, but there is no guarantee that such agreements will be executed [188]. - The company anticipates that its Sponsor, officers, and directors may identify stockholders for privately negotiated purchases [172].